The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
GW9662, a potent antagonist of PPAR γ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR γ agonist rosiglitazone, independently of PPAR γ activation
Open accessAbstract
Peroxisome proliferator‐activated receptor gamma (PPAR γ), a member of the nuclear receptor superfamily, is activated by several compounds, including the thiazolidinediones. In addition to being a therapeutic target for obesity, hypolipidaemia and diabetes, perturbation of PPAR γ signalling is now believed to be a strategy for treatment of several cancers, including breast. Although differential expression of PPAR γ is observed in tumours compared to normal tissues and PPAR γ agonists have been shown to inhibit tumour cell growth and survival, the interdependence of these observations is unclear. This study demonstrated that the potent, irreversible and selective PPAR γ antagonist GW9662 prevented activation of PPAR γ and inhibited growth of human mammary tumour cell lines. Controversially, GW9662 prevented rosiglitazone‐mediated PPAR γ activation, but enhanced rather than reversed rosiglitazone‐induced growth inhibition. As such, these data support the existence of PPAR γ‐independent pathways and question the central belief that PPAR γ ligands mediate their anticancer effects via activation of PPAR γ. British Journal of Pharmacology (2004) 143, 933–937. doi:10.1038/sj.bjp.0705973
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 566
Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024038127156 · Cited by 228
15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells
Clay, C. E., Monjazeb, A., Thorburn, J., Chilton, F. H., & High, K. P. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200224-jlr200 · Cited by 103 · cited 3×
“Furthermore, apoptosis induced by the PPARg ligand 15-deoxy D12,14-prostaglandin J2 has also been shown to occur independently of PPARg activation (Clay et al., 2002).”
BackgroundResult
Cited by
Mirza, A. Z., Althagafi, I. I., & Shamshad, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.067 · Cited by 544
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Luteolin Enhances Insulin Sensitivity via Activation of PPARγ Transcriptional Activity in Adipocytes
Ding, L., Jin, D., & Chen, X. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.07.009 · Cited by 159
“Although it has also been reported that GW9662 might act through other PPARγ-independent pathways, selectively antagonizing PPARγ activity is the primary action of GW9662 [37].”
BackgroundXu, Y., Yu, T., Ma, G., Zheng, L., Jiang, X., Yang, F., Wang, Z., Li, N., He, Z., Song, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62556 · Cited by 110
Ramos-Nino, M. E., MacLean, C. D., & Littenberg, B. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-17 · Cited by 92
Metadata
- Authors
- Seargent, J. M., Yates, E. A., & Gill, J. H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 143
- Issue
- 8
- Pages
- 933-937
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2002276672
- Cited by
- 192
- References
- 3
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.